Payment overview · 2025
General Payments
$142.62
7 reported records · 6 companies
Healthcare provider profile · identity verified
Sara Ines Gitte, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUMMERFIELD, FL · NPI 1629348966
Verified facts
What the public records show
CMS Open Payments records show Sara Ines Gitte, MD received $142.62 in general payments during 2025 across 7 reported records.
Exact Sciences Corporation accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.56 | 31.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.35 | 18.5% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $25.57 | 17.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.23 | 12.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.23 | 11.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.68 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $142.62 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.56 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
162 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
55 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1049 | 285 |
| Atorvastatin Calcium | Atorvastatin Calcium | 972 | 288 |
| Amlodipine Besylate | Amlodipine Besylate | 821 | 243 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 751 | 231 |
| Simvastatin | Simvastatin | 592 | 177 |
| Lisinopril | Lisinopril | 582 | 166 |
| Omeprazole | Omeprazole | 572 | 184 |
| Losartan Potassium | Losartan Potassium | 561 | 158 |
| Gabapentin | Gabapentin | 451 | 135 |
| Metformin Hcl | Metformin Hcl | 374 | 112 |
| Sertraline Hcl | Sertraline Hcl | 360 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 326 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 316 | 89 |
| Alprazolam | Alprazolam | 305 | 88 |
| Metoprolol Tartrate | Metoprolol Tartrate | 296 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 291 | 86 |
| Trazodone Hcl | Trazodone Hcl | 280 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 266 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 241 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 65 |
| Montelukast Sodium | Montelukast Sodium | 206 | 65 |
| Citalopram Hbr | Citalopram Hydrobromide | 194 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 182 | 46 |
| Mirtazapine | Mirtazapine | 181 | 54 |
| Furosemide | Furosemide | 167 | 51 |
| Alendronate Sodium | Alendronate Sodium | 165 | 49 |
| Eliquis | Apixaban | 162 | 51 |
| Ezetimibe | Ezetimibe | 161 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 42 |
| Mounjaro | Tirzepatide | 137 | 26 |
| Atenolol | Atenolol | 136 | 33 |
| Meloxicam | Meloxicam | 132 | 51 |
| Carvedilol | Carvedilol | 128 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 36 |
| Synthroid | Levothyroxine Sodium | 126 | 39 |
| Valsartan | Valsartan | 125 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 45 |
| Ozempic | Semaglutide | 122 | 27 |
| Allopurinol | Allopurinol | 121 | 33 |
| Glipizide Er | Glipizide | 111 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 103 | 29 |
| Tramadol Hcl | Tramadol Hcl | 99 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 47 |
| Buspirone Hcl | Buspirone Hcl | 88 | 33 |
| Prednisone | Prednisone | 86 | 59 |
| Spironolactone | Spironolactone | 83 | 26 |
| Methylprednisolone | Methylprednisolone | 80 | 68 |
| Estradiol | Estradiol | 79 | 29 |
| Metformin Hcl Er | Metformin Hcl | 79 | 22 |
| Lorazepam | Lorazepam | 78 | 21 |
| Lovastatin | Lovastatin | 77 | 22 |
| Temazepam | Temazepam | 75 | 18 |
| Potassium Chloride | Potassium Chloride | 72 | 26 |
| Bupropion Xl | Bupropion Hcl | 71 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 20 |
| Clonazepam | Clonazepam | 65 | 13 |
| Warfarin Sodium | Warfarin Sodium | 65 | 15 |
| Propranolol Hcl | Propranolol Hcl | 64 | 18 |
| Azithromycin | Azithromycin | 63 | 57 |
| Benazepril Hcl | Benazepril Hcl | 63 | 17 |
| Famotidine | Famotidine | 63 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 48 |
| Finasteride | Finasteride | 57 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 28 |
| Paxlovid | Nirmatrelvir/Ritonavir | 55 | 55 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 20 |
| Glipizide | Glipizide | 53 | 18 |
| Eszopiclone | Eszopiclone | 52 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 12 |
| Donepezil Hcl | Donepezil Hcl | 48 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 41 | 11 |
| Ramipril | Ramipril | 41 | 11 |
| Xarelto | Rivaroxaban | 41 | 11 |
| Diazepam | Diazepam | 39 | suppressed |
| Fenofibrate | Fenofibrate | 39 | 12 |
| Valacyclovir | Valacyclovir Hcl | 39 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | 16 |
| Celecoxib | Celecoxib | 37 | 12 |
| Enalapril Maleate | Enalapril Maleate | 37 | 11 |
| Cefuroxime | Cefuroxime Axetil | 36 | 31 |
| Acyclovir | Acyclovir | 35 | 12 |
| Amoxicillin | Amoxicillin | 34 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 25 |
| Cephalexin | Cephalexin | 31 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | 13 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 31 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 11 |
| Topiramate | Topiramate | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | 11 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | 13 |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Nystatin | Nystatin | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | 11 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Fluconazole | Fluconazole | 15 | 12 |
| Ibuprofen | Ibuprofen | 15 | 11 |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $142.62 · 7 records | Exact Sciences Corporation | ABRYSVO, COMIRNATY, LEQVIO, PREVNAR 20, TARPEYO, The Cologuard Plus Collection Kit, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error